Exciting News in Lung Cancer Treatment
Dr. Jason Porter joins Dr. Maya Khalil, Dr. Brian Mitzman, and Dr. Rami Manochakian in discussing the strides made in improving patient outcomes with immunotherapy and targeted therapies for non-small cell lung cancer (NSCLC).
The group talks about several new clinical trials demonstrating promising results for high PD-L1 expression NSCLC patients and EGFR-mutated NSCLC.
They debate choosing between neoadjuvant and adjuvant therapies in early-stage lung cancer. They mention neoadjuvant therapy offers benefits like better tolerance and assessment of treatment response before surgery, though there are still concerns about missing risk factors and adverse reactions. The group agrees that this is a complex decision for physicians overall.